$REUN News
Last published 3y ago
- 3y agoREUNReunion Neuroscience Inc. and MPM BioImpact Announce Completion of Plan of ArrangementGlobeNewswireTORONTO, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX:REUN, NASDAQ:REUN) ("Reunion" or the "Company"), a clinical-stage biopharmaceutical company committed to developing innovative
- 3y agoREUNReunion Neuroscience Inc. Obtains Final Court Order for Proposed Plan of ArrangementGlobeNewswireTORONTO, July 14, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX:REUN, NASDAQ:REUN) ("Reunion" or the "Company"), a clinical-stage biopharmaceutical company committed to developing innovative
- 3y agoREUNReunion Neuroscience Inc. Shareholders Approve Proposed Plan of ArrangementGlobeNewswireTORONTO, July 13, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX:REUN, NASDAQ:REUN) ("Reunion" or the "Company"), a clinical-stage biopharmaceutical company committed to developing innovative and
- 3y agoREUNReunion Neuroscience Reports Fiscal Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate UpdateGlobeNewswireCommon Shareholders to Receive Consideration of US$1.12 Per Share in Cash from the Arrangement Agreement with MPM BioImpact; Special Shareholder Meeting Scheduled July 12 Presented Encouraging Phase 1 Final Analysis at
- 3y agoAAICDMREUNWTTMoore Kuehn Encourages WTT, DM, AAIC, and REUN Investors to Contact Law FirmPR NewswireNEW YORK, June 6, 2023 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following
- 3y agoAAICDMREUNWTTMoore Kuehn Encourages REUN, AAIC, DM, and WTT Investors to Contact Law FirmGlobeNewswireNEW YORK, June 02, 2023 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the
- 3y agoREUNReunion Neuroscience Announces US$13.1 Million Take-Private Transaction with MPM BioImpactGlobeNewswireReunion Common Shareholders to Receive Consideration of US$1.12 Per Share in Cash Represents a 43.1% Premium to the 30-Day Volume Weighted Average Price Reunion Presents Encouraging Phase 1 Final Analysis at American
- 3y agoREUNReunion Neuroscience Announces Presentation at 2023 Bloom Burton & Co. Healthcare Investor ConferenceGlobeNewswireTORONTO, April 25, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ:REUN, TSX:REUN) ("Reunion" or "the Company"), a clinical-stage biopharmaceutical company committed to developing innovative and patented
- 3y agoREUNReunion Neuroscience Receives NASDAQ Notification Regarding Minimum Bid Price DeficiencyGlobeNewswireTORONTO, April 25, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ:REUN, TSX:REUN) ("Reunion" or "the Company"), a clinical-stage biopharmaceutical company committed to developing innovative and patented
- 3y agoREUNReunion Neuroscience Appoints Dr. Fred Grossman to Board of DirectorsGlobeNewswire- Seasoned Psychiatrist and Global Pharmaceutical R&D Executive with Over Two Decades of Experience in Clinical Development, Including at Eli Lilly, Johnson & Johnson, Bristol Myers Squibb and Sunovion
- 3y agoREUNReunion Neuroscience Abstract Accepted for Poster Presentation at 2023 ASCP Annual MeetingGlobeNewswireTORONTO, March 27, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ:REUN, TSX:REUN) ("Reunion" or "the Company"), a clinical-stage biopharmaceutical company committed to developing innovative and patented
- 3y agoREUNReunion Neuroscience Files Lawsuit Against Mindset PharmaGlobeNewswireTORONTO, March 13, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ:REUN, TSX:REUN) ("Reunion" or "the Company"), a clinical-stage biopharmaceutical company committed to developing innovative and patented
- 3y agoREUNReunion Neuroscience to Participate in the Oppenheimer Annual Healthcare ConferenceGlobeNewswireTORONTO, March 07, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ:REUN, TSX:REUN) ("Reunion" or "the Company"), a clinical-stage biopharmaceutical company committed to developing innovative and patented
- 3y agoREUNReunion Neuroscience Provides Business Update and Reports Fiscal Third Quarter 2023 Financial ResultsGlobeNewswireCompany Completed Phase 1 Interim Data Analysis for Lead Asset, RE104, Which Showed Strong Safety and Tolerability with Differentiated Profile; Final Data Anticipated in Mid-2023 Continued to Strengthen
- 3y agoREUNReunion Neuroscience Schedules Fiscal Third Quarter 2023 Conference Call for Tuesday, February 14, 2023, at 8:30 A.M. ETGlobeNewswireTORONTO, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ:REUN, TSX:REUN) ("Reunion" or "the Company"), a biopharmaceutical company committed to developing innovative and patented therapeutic
- 3y agoREUNReunion Neuroscience Appoints Robert Alexander as Chief Medical OfficerGlobeNewswireTORONTO, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ:REUN, TSX:REUN) ("Reunion" or "the Company"), a biopharmaceutical company committed to developing innovative and patented therapeutic
- 3y agoREUNReunion Neuroscience Inc. Completes Interim Data Analysis for Phase 1 Clinical Trial with Novel Serotonergic Psychedelic RE104GlobeNewswireTORONTO, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ:REUN, TSX:REUN) ("Reunion" or "the Company"), a biopharmaceutical company committed to developing innovative and patented therapeutic
- 3y agoREUNReunion Neuroscience Inc. Provides 2023 Corporate UpdateGlobeNewswireCompany Plans to Report Phase 1 Interim Analysis for RE104 in Q1 2023 and Include Data Differentiating its Safety, Tolerability and Pharmacodynamic Profile from Other Psychedelics in Clinical Development On Track to
- 3y agoREUNReunion Neuroscience Inc. to Participate in Upcoming Investor Conferences in DecemberGlobeNewswireTORONTO, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ:REUN, TSX:REUN), a biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental
- 3y agoREUNReunion Neuroscience Puts in Place At-The-Market Equity FacilityGlobeNewswireTORONTO, Nov. 18, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX:REUN, NASDAQ:REUN) ("Reunion" or the "Company"), a biopharmaceutical company committed to developing innovative and patented therapeutic
- 3y agoREUNReunion Neuroscience Inc. Provides Business Update and Reports Fiscal Second Quarter 2023 Financial ResultsGlobeNewswireCompleted RE104 Phase 1 prespecified dose cohorts and on track to deliver interim Phase 1 analysis in the first calendar quarter of 2023.Appointed Greg Mayes as President and Chief Executive Officer, with Joseph del
- 4y agoREUNReunion Neuroscience Schedules Fiscal Second Quarter 2023 Conference Call for Monday, November 14, 2022, at 8:30 A.M. ETGlobeNewswireTORONTO, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ:REUN, TSX:REUN) ("Reunion" or the "Company"), a biopharmaceutical company committed to developing innovative therapeutic solutions
- 4y agoREUNReunion Neuroscience to Present at Upcoming November ConferencesGlobeNewswireTORONTO, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ:REUN, TSX:REUN) ("Reunion" or the "Company"), a biopharmaceutical company committed to developing innovative therapeutic solutions
- 4y agoREUNReunion Neuroscience Appoints Chief Financial Officer and Vice President, Medical AffairsGlobeNewswireTORONTO, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ:REUN, TSX:REUN) ("Reunion" or the "Company"), a biopharmaceutical company committed to developing innovative therapeutic solutions
- 4y agoREUNReunion Neuroscience CEO to Participate on Panel at 2022 Horizons Perspectives on Psychedelics ConferenceGlobeNewswireTORONTO, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX:REUN, NASDAQ:REUN) ("Reunion" or the "Company"), a leader in novel serotonergic psychedelic drug development committed to innovating
- 4y agoREUNReunion Neuroscience Inc. Announces Executive ChangesGlobeNewswireTORONTO, Oct. 07, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX:REUN, NASDAQ:REUN) ("Reunion" or the "Company"), a leader in novel psychedelic drug development committed to innovating therapeutic
- 4y agoREUNReunion Neuroscience to Participate in the Cantor Neurology & Psychiatry ConferenceGlobeNewswireTORONTO, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX:REUN, NASDAQ:REUN) ("Reunion"), or ("the Company"), a global leader in the discovery and development of innovative psychedelic-inspired therapeutics for improved mental health ou
- 4y agoREUNReunion Neuroscience Inc. Announces Results of Annual General and Special Shareholder MeetingGlobeNewswireTORONTO, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX:REUN, NASDAQ:REUN) ("Reunion" or the "Company") today announced the results of the votes held at its September 29, 2022 Annual General and Special Meeting of shareholders (the "
- 4y agoREUNReunion Neuroscience Inc. Appoints Greg Mayes as President and Chief Executive OfficerGlobeNewswireTORONTO, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX:REUN, NASDAQ:REUN) ("Reunion" or the "Company"), a leader in novel psychedelic drug development committed to innovating therapeutic solutions for mental health conditions by dev
- 4y agoREUNReunion Neuroscience Inc. to Participate in Upcoming Investor ConferencesGlobeNewswireTORONTO, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX:REUN, NASDAQ:REUN) ("Reunion"), or ("the Company"), a global leader in the discovery and development of innovative psychedelic-inspired therapeutics for improved mental health o
- 4y agoREUNReunion Neuroscience Inc. Announces 2022 Annual General Meeting of ShareholdersGlobeNewswireTORONTO, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX:REUN, NASDAQ:REUN) ("Reunion"), or ("the Company"), a global leader in the discovery and development of innovative of psychedelic-inspired therapeutics for improved mental health